New Study from Crohn's & Colitis Foundation of America Uncovers Gaps in...
NEW YORK Sept. 6 2016 PRNewswireUSNewswire Patients living with inflammatory bowel diseases IBD may be at greater risk for malnourishment. Some studies have shown that as many as 80 percent of all...
View ArticleValeant And Progenics Announce The U.S. Commercial Launch Of FDAApproved...
LAVAL Quebec Sept. 6 2016 PRNewswire &160;Valeant Pharmaceuticals International Inc. NYSE VRX and TSX VRX "Valeant" and Progenics Pharmaceuticals Inc. Nasdaq PGNX "Progenics" today announced the...
View ArticleImmune Pharmaceuticals Receives $2 Million Investment in Common Stock at...
NEW YORK Sept. 7 2016 PRNewswire &160;Immune Pharmaceuticals Inc. NASDAQ IMNP "Immune" a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of...
View ArticleTakeda Launches Wearable Digital Technology Pilot Program to Support Patients...
DEERFIELD Ill. Sept. 7 2016 PRNewswire &160;Today Takeda Pharmaceuticals U.S.A. Inc. "Takeda" announced the launch of a pilot digital technology program to support patients and physicians with the...
View ArticleThe gut bacteria of zoo monkeys resemble those of humans U of M researchers find
Wikimedia CommonsBjrn Christian TrrissenRedshanked doucs have a rumen much like a cow.Monkeys living in captivity develop microbiomes communities of bacteria and other microbes in their guts that...
View ArticleHumira provides effective nonsteroid alternative for eye inflammation
Patients suffering from noninfectious uveitis a group of diseases that causes eye inflammation can get effective treatment from a corticosteroid alternative that has previously been approved for...
View ArticleExpress Scripts Launches Inflammatory Conditions Care Value ProgramSM Making...
ST. LOUIS Sept. 8 2016 PRNewswire &160;Express Scripts NASDAQ ESRX today launched its Inflammatory Conditions Care Value Program&8480; a comprehensive approach to control costs and improve care...
View ArticleRedHill Biopharma Announces Phase IbII Study with YELIVA Initiated for...
The Phase IbII clinical study is intended to evaluate the safety and efficacy of YELIVA ABC294640 in patients with refractory or relapsed multiple myeloma and is supported by a $2 million grant from...
View ArticleRedHill Biopharma Announces Phase IbII Study with YELIVATM Initiated for...
The Phase IbII clinical study is intended to evaluate the safety and efficacy of YELIVATMÂABC294640 in patients with refractory or relapsed multiple myeloma and is supported by a $2 million grant from...
View ArticleSoligenix and SciClone Establish Regional Licensing Agreement for SGX942 a...
PRINCETON N.J. and FOSTER CITY Calif. Sept. 12 2016 PRNewswire &160;Soligenix Inc. OTCQB SNGX a latestage biopharmaceutical company focused on developing and commercializing products to treat rare...
View ArticlePhRMA and Lupus Foundation of America Report More Than 300 Medicines in...
WASHINGTON Sept. 12 2016 PRNewswire &160;A new report released by the Pharmaceutical Research and Manufacturers of America PhRMA and Lupus Foundation of America highlights tremendous progress in...
View ArticleCelgene Data Offer A Rorschach Test To Wall Street
For Celgene the giant biotechnology company that turned thalidomide into a series of bigselling blood cancer drugs the most watched event of the fall was supposed to be the release of data on GED0301 a...
View ArticleRedHill Biopharma Announces Research Collaboration with Stanford University...
TelAviv Israel September 12 2016 B3C newswire RedHill Biopharma Ltd. NASDAQ RDHL TASE RDHL RedHill or the Company a biopharmaceutical company primarily focused on development and commercialization of...
View ArticleRedHill Biopharma Announces Research Collaboration with Stanford University...
TELAVIV Israel Sept. 12 2016 GLOBE NEWSWIRE RedHill Biopharma Ltd. NASDAQRDHL TASERDHL "RedHill" or the "Company" a biopharmaceutical company primarily focused on...
View ArticleCelgene reports Phase Ib Crohn's data
Celgene Corp. NASDAQCELG said 12week interim data showed that oral mongersen GED0301 led to endoscopic improvement and clinical response and remission in "a proportion of patients" across all treatment...
View ArticleKezar Life Sciences Announces Initiation of Phase 1 Clinical Program for Lead...
SOUTH SAN FRANCISCO Calif. Sept. 13 2016 PRNewswire &160;Kezar Life Sciences a company focused on the discovery and development of drugs targeting protein homeostasis announced today the initiation...
View ArticleFrost & Sullivan Acknowledges the Role Played by Cell Science Systems' Alcat...
MOUNTAIN VIEW Calif. Sept. 13 2016 PRNewswire &160;Based on its recent analysis of the food intolerance testing market Frost & Sullivan recognizes Cell Science Systems Corporation CSS with...
View ArticleCelgene baffles market with Crohn's drug data
Celgene has announced topline results from an early stage trial of its mongersen a closelywatched potential treatment for Crohn's disease.Back in 2014 Celgene paid Ireland's Nogra Pharma $710 million...
View ArticleCelgene's Vague Crohn Disease Drug Data Confuse Analysts
ArticleCelgenes announcement regarding its promising oral candidate to treat Crohns disease was difficult to interpret for some financial analysts.
View Article